Eyal Gabbai

Director at NurExone Biologic.

Earliest Form D on file: Jul 2026

Filed Jul 2, 2026

NurExone Biologic

Exosome drug for acute spinal cord injury

Biotech

Named, Director.

$442K

sold of $442K offered

Network

At NurExone Biologic

6 people

Eran Ovadya
Together on 1 filing
Executive Officer, signed as Chief Financial Officer
Lior Shaltiel
Together on 1 filing
Executive Officer, Director
Yoram Drucker
Together on 1 filing
Executive Officer, Director
James Richardson
Together on 1 filing
Director
Oded Orgil
Together on 1 filing
Director
Gadi Riesenfeld
Director